Value Insights
How product value is built, defended, and negotiated. Writing for access, HEOR, and medical affairs teams.
CONITEC and IETS are redefining what evidence counts as sufficient. Does your team know?
8 min readHTA StrategyThree HTA agencies. No AI rules. And dossiers are already arriving with AI inside.
9 min readMarket AccessAI in Pharma Market Access: Where It Already Works — and Where It Still Doesn't
14 min readHTA StrategyWhat Is a Global Value Dossier and How AI Is Transforming It
14 min readAn Illustrative Case: How Automation Can Cut HTA Dossier Preparation Time
A stage-by-stage reconstruction of where time really goes in an HTA dossier and how much automation can compress.
How to Measure Medical Affairs Impact on Market Access Decisions
Most medical affairs teams measure how much they do, not what they change. In access, that difference is everything.
Quantus AI vs. Traditional HEOR Consulting: When to Use Each Model and Why
An honest guide to choosing between traditional HEOR consulting and a product-based model for market access work.
ICER and Cost-Effectiveness Thresholds in Latin America: What Market Access Teams Need to Know in 2026
Three countries have set explicit thresholds. The rest still rely on GDP-based shortcuts the WHO no longer endorses.
How to Build Payer Value Stories that Resonate in Latin American Health Systems
The frameworks taught in Boston and London work differently in Bogotá, São Paulo, and Mexico City.
The market access skills crisis nobody is seeing, and the framework to solve it
Pharma companies face a market access talent gap that is growing faster than their development plans.